EBR Systems, the heart device hopeful heavily backed by high-profile investors, including private equity veteran Mark Carnegie and major superannuation funds, has secured approval from authorities in the United States to begin selling its technology within months.
The Food and Drug Administration approval means the company can begin generating revenues. Its wireless pacing system prevents heart failure – a market that could be worth as much as $6 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.